Curcumin-decorated nanoliposomes with very high affinity for amyloid-β1-42 peptide

Biomaterials

Volumn 32, Issue 6, 2011, Pages 1635-1645

  Mourtas, Spyridon ^a   Canovi, Mara ^b   Zona, Cristiano ^c   Aurilia, Dario ^c   Niarakis, Anna ^a   La Ferla, Barbara ^c   Salmona, Mario ^b   Nicotra, Francesco ^c   Gobbi, Marco ^b   Antimisiaris, Sophia G ^a,d  

^a UNIVERSITY OF PATRAS   (Greece)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c UNIVERSITY OF MILANO BICOCCA   (Italy)

^d INSTITUTE OF CHEMICAL ENGINEERING SCIENCES   (Greece)

Author keywords

Alzheimer disease (AD); Amyloid beta (A ); Click chemistry; Curcumin; Liposomes; Structure

Indexed keywords

ALZHEIMER DISEASE; AMYLOID BETAS; CLICK CHEMISTRY; CURCUMIN; STRUCTURE;

DIAGNOSIS; DISEASE CONTROL; GLYCOPROTEINS; LIPOSOMES; PLASMONS; PROTEINS; SURFACE PLASMON RESONANCE;

PHOSPHOLIPIDS;

AMYLOID BETA PROTEIN[1-42]; CURCUMIN; LIPOSOME; NANOLIPOSOME; NANOPARTICLE; PHOSPHOLIPID; PLASMA PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CHEMICAL REACTION; CONJUGATION; DRUG DELIVERY SYSTEM; LIPID COMPOSITION; PRIORITY JOURNAL; PROTEIN IMMOBILIZATION; PROTEIN INTERACTION; PROTEIN STRUCTURE; REACTION ANALYSIS; SURFACE PLASMON RESONANCE; ZETA POTENTIAL;

AMYLOID BETA-PEPTIDES; CLICK CHEMISTRY; CURCUMIN; LIPOSOMES; SURFACE PLASMON RESONANCE;

EID: 78650300340     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2010.10.027     Document Type: Article

References (60)

1. Brookmeyer R., Gray S., Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health 1998, 88(9):1337-1342.
2. Alzheimer disease research: about Alzheimer American Health Assistance Foundation. http://wwwahaforg/alzheimers/about/2000-2010.
3. Brookmeyer R., Corrada M.M., Curriero F.C., Kawas C. Survival following a diagnosis of Alzheimer disease. Arch Neurol 2002, 59(11):1764-1767.
4. Ferri C.P., Prince M., Brayne C., Brodaty H., Fratiglioni L., Ganguli M., et al. Global prevalence of dementia: a Delphi consensus study. Lancet 2005, 366(9503):2112-2117.
5. Alzheimer Europe and Eurostat http://www.AlzheimerEurope.org.
6. Citron M. Alzheimer's disease: strategies for disease modification. Nat Rev Drug Discov 2010, 9(5):387-398.
7. Mann D.M., Iwatsubo T., Ihara Y., Cairns N.J., Lantos P.L., Bogdanovic N., et al. Predominant deposition of amyloid-beta 42(43) in plaques in cases of Alzheimer's disease and hereditary cerebral hemorrhage associated with mutations in the amyloid precursor protein gene. Am J Pathol 1996, 148(4):1257-1266.
8. Selkoe D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 2001, 81(2):741-766.
9. Siemers E., DeMattos R.B., May P.C., Dean R.A. Role of biochemical Alzheimer's disease biomarkers as end points in clinical trials. Biomark Med 2010, 4(1):81-89.
10. Yin Y.I., Bassit B., Zhu L., Yang X., Wang C., Li Y.M. {gamma}-secretase substrate concentration modulates the abeta42/abeta40 ratio: implications for Alzheimer disease. J Biol Chem 2007, 282(32):23639-23644.
11. Barnham K.J., Masters C.L., Bush A.I. Neurodegenerative diseases and oxidative stress. Nat Rev Drug Discov 2004, 3(3):205-214.
12. Lambert M.P., Barlow A.K., Chromy B.A., Edwards C., Freed R., Liosatos M., et al. Diffusible, nonfibrillar ligands derived from abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A 1998, 95(11):6448-6453.
13. Cleary J.P., Walsh D.M., Hofmeister J.J., Shankar G.M., Kuskowski M.A., Selkoe D.J., et al. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci 2005, 8(1):79-84.
14. Walsh D.M., Selkoe D.J. A beta oligomers - a decade of discovery. J Neurochem 2007, 101(5):1172-1184.
15. Haass C., Selkoe D.J. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 2007, 8(2):101-112.
16. Carrell R.W., Mushunje A., Zhou A. Serpins show structural basis for oligomer toxicity and amyloid ubiquity. FEBS Lett 2008, 582(17):2537-2541.
17. Pahnke J., Walker L.C., Scheffler K., Krohn M. Alzheimer's disease and blood-brain barrier function-why have anti-beta-amyloid therapies failed to prevent dementia progression?. Neurosci Biobehav Rev 2009, 33(7):1099-1108.
18. Dasilva K.A., Shaw J.E., McLaurin J. Amyloid-beta fibrillogenesis: structural insight and therapeutic intervention. Exp Neurol 2010, 223(2):311-321.
19. Findeis M.A. The role of amyloid beta peptide 42 in Alzheimer's disease. Pharmacol Ther 2007, 116(2):266-286.
20. De Felice F.G., Ferreira S.T. Beta-amyloid production, aggregation, and clearance as targets for therapy in Alzheimer's disease. Cell Mol Neurobiol 2002, 22(5-6):545-563.
21. Greenberg S.M., Grabowski T., Gurol M.E., Skehan M.E., Nandigam R.N., Becker J.A., et al. Detection of isolated cerebrovascular beta-amyloid with Pittsburgh compound B. Ann Neurol 2008, 64(5):587-591.
22. Look G.C., Jerecic J., Cherbavaz D.B., Pray T.R., Breach J.C., Crosier W.J., et al. Discovery of ADDL-targeting small molecule drugs for Alzheimer's disease. Curr Alzheimer Res 2007, 4(5):562-567.
23. Matsuoka Y., Saito M., LaFrancois J., Gaynor K., Olm V., Wang L., et al. Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to beta-amyloid. J Neurosci 2003, J23(1):29-33.
24. Sagare A., Deane R., Bell R.D., Johnson B., Hamm K., Pendu R., et al. Clearance of amyloid-beta by circulating lipoprotein receptors. Nat Med 2007, 13(9):1029-1031.
25. Shen Y., Yu L.C. Potential protection of curcumin against hypoxia-induced decreases in beta-III tubulin content in rat prefrontal cortical neurons. Neurochem Res 2008, 33(10):2112-2117.
26. Zhao B.L., Li X.J., He R.G., Cheng S.J., Xin W.J. Scavenging effect of extracts of green tea and natural antioxidants on active oxygen radicals. Cell Biophys 1989, 14(2):175-185.
27. Thomas T., Nadackal T.G., Thomas K. Aspirin and non-steroidal anti-inflammatory drugs inhibit amyloid-beta aggregation. Neuroreport 2001, 12(15):3263-3267.
28. Ono K., Hasegawa K., Naiki H., Yamada M. Curcumin has potent anti-amyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro. J Neurosci Res 2004, M75(6):742-750.
29. Kim H., Park B.S., Lee K.G., Choi C.Y., Jang S.S., Kim Y.H., et al. Effects of naturally occurring compounds on fibril formation and oxidative stress of beta-amyloid. J Agric Food Chem 2005, 53(22):8537-8541.
30. Yang F., Lim G.P., Begum A.N., Ubeda O.J., Simmons M.R., Ambegaokar S.S., et al. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem 2005, 280(7):5892-5901.
31. Kim D.S., Park S.Y., Kim J.K. Curcuminoids from curcuma longa L. (zingiberaceae) that protect PC12 rat pheochromocytoma and normal human umbilical vein endothelial cells from abeta(1-42) insult. Neurosci Lett 2001, 303(1):57-61.
32. Re F., Airoldi C., Zona C., Masserini M., La Ferla B., Quattrocchi N., et al. Beta amyloid aggregation Inhibitors: small molecules as candidate drugs for therapy of Alzheimer's disease. Curr Med Chem 2010, [Epub ahead of print].
33. Ganguli M., Dodge H.H., Chen P., Belle S., DeKosky S.T. Ten-year incidence of dementia in a rural elderly US community population: the MoVIES project. Neurology 2000, 54(5):1109-1116.
34. Reinke A.A., Gestwicki J.E. Structure-activity relationships of amyloid beta-aggregation inhibitors based on curcumin: influence of linker length and flexibility. Chem Biol Drug Des 2007, 70(3):206-215.
35. Anand P., Thomas S.G., Kunnumakkara A.B., Sundaram C., Harikumar K.B., Sung B., et al. Biological activities of curcumin and its analogues (congeners) made by man and mother nature. Biochem Pharmacol 2008, 76(11):1590-1611.
36. Bernabe-Pineda M., Ramirez-Silva M.T., Romero-Romo M., Gonzalez-Vergara E., Rojas-Hernandez A. Determination of acidity constants of curcumin in aqueous solution and apparent rate constant of its decomposition. Spectrochim Acta A Mol Biomol Spectrosc 2004, 60(5):1091-1097.
37. Wang Y.J., Pan M.H., Cheng A.L., Lin L.I., Ho Y.S., Hsieh C.Y., et al. Stability of curcumin in buffer solutions and characterization of its degradation products. J Pharm Biomed Anal 1997, 15(12):1867-1876.
38. Tonnesen H.H., Karlsen J. Studies on curcumin and curcuminoids. VI. Kinetics of curcumin degradation in aqueous solution. Z Lebensm Unters Forsch 1985, 180(5):402-404.
39. Montet X., Funovics M., Montet-Abou K., Weissleder R., Josephson L. Multivalent effects of RGD peptides obtained by nanoparticle display. J Med Chem 2006, 49(20):6087-6093.
40. Hong S., Leroueil P.R., Majoros I.J., Orr B.G., Baker J.R., Banaszak Holl M.M. The binding avidity of a nanoparticle-based multivalent targeted drug delivery platform. Chem Biol 2007, 14(1):107-115.
41. Tassa C., Duffner J.L., Lewis T.A., Weissleder R., Schreiber S.L., Koehler A.N., et al. Binding affinity and kinetic analysis of targeted small molecule-modified nanoparticles. Bioconjug Chem 2010, 21(1):14-19.
42. Antimisiaris S.G., Kallinteri P., Fatouros D. Liposomes and drug delivery. Pharmaceutical manufacturing handbook production and processes 2008, 443-533. John Wiley & Sons. S.C. Gad (Ed.).
43. Said Hassane F., Frisch B., Schuber F. Targeted liposomes: convenient coupling of ligands to preformed vesicles using "click chemistry. Bioconjug Chem 2006, 17(3):849-854.
44. Cavalli S., Tipton A.R., Overhand M., Kros A. The chemical modification of liposome surfaces via a copper-mediated [3 + 2] azide-alkyne cycloaddition monitored by a colorimetric assay. Chem Commun (Camb) 2006, 30:3193-3195.
45. Hein C.D., Liu X.M., Wang D. Click chemistry, a powerful tool for pharmaceutical sciences. Pharm Res 2008, 25(10):2216-2230.
46. Frisch B., Hassane F.S., Schuber F. Conjugation of ligands to the surface of preformed liposomes by click chemistry. Methods Mol Biol 2010, 605:267-277.
47. Thoma K., Rombach R., Ullmann E. Thin-layer chromatographic differentiation of homologous polyethylene glicols. Sci Pharm 1964, 32:216-224.
48. Dittmer J.C., Lester R.L. A simple, specific spray for the detection of phospholipids on thin-layer chromatograms. J Lipid Res 1964, 15:126-127.
49. 4. Synth Commun 2003, 33:999-1004.
50. Horne W.S., Stout C.D., Ghadiri M.R. A heterocyclic peptide nanotube. J Am Chem Soc 2003, 125(31):9372-9376.
51. Usta M., Wortelboer H.M., Vervoort J., Boersma M.G., Rietjens I.M., van Bladeren P.J., et al. Human glutathione S-transferase-mediated glutathione conjugation of curcumin and efflux of these conjugates in Caco-2 cells. Chem Res Toxicol 2007, 20(12):1895-1902.
52. Kokkona M., Kallinteri P., Fatouros D., Antimisiaris S.G. Stability of SUV liposomes in the presence of cholate salts and pancreatic lipases: effect of lipid composition. Eur J Pharm Sci 2000, 9(3):245-252.
53. Sohma Y., Sasaki M., Hayashi Y., Kimura T., Kiso Y. Design and synthesis of a novel water-soluble Abeta 1-42 isopeptide: an efficient strategy for the preparation of Alzheimer's disease-related peptide, Abeta 1-42, via O-N intramolecular acyl migration reaction. Tetrahedron Lett 2004, 45(31):5965-5968.
54. Taniguchi A., Sohma Y., Hirayama Y., Mukai H., Kimura T., Hayashi Y., et al. "Click peptide": pH-triggered in situ production and aggregation of monomer abeta1-42. Chembiochem 2009, 10(4):710-715.
55. Balducci C., Beeg M., Stravalaci M., Bastone A., Sclip A., Biasini E., et al. Synthetic amyloid-beta oligomers impair long-term memory independently of cellular prion protein. Proc Natl Acad Sci U S A 2010, 107(5):2295-2300.
56. Dahlgren K.N., Manelli A.M., Stine W.B., Baker L.K., Krafft G.A., LaDu M.J. Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J Biol Chem 2002, 277(35):32046-32053.
57. Bravman T., Bronner V., Lavie K., Notcovich A., Papalia G.A., Myszka D.G. Exploring "one-shot" kinetics and small molecule analysis using the ProteOn XPR36 array biosensor. Anal Biochem 2006, 358(2):281-288.
58. Gobbi M., Re F., Canovi M., Beeg M., Gregori M., Sesana S., et al. Lipid-based nanoparticles with high binding affinity for amyloid-beta(1-42) peptide. Biomaterials 2010, 31(25):6519-6529.
59. Lallana E., Fernandez-Megia E., Riguera R. Surpassing the use of copper in the click functionalization of polymeric nanostructures: a strain-promoted approach. J Am Chem Soc 2009, 131(16):5748-5750.
60. Yanagisawa D., Shirai N., Amatsubo T., Taguchi H., Hirao K., Urushitani M., et al. Relationship between the tautomeric structures of curcumin derivatives and their abeta-binding activities in the context of therapies for Alzheimer's disease. Biomaterials 2010, 31(14):4179-4185.